Shanghai Hile Bio-Technology Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000022T4
CNY
4.45
-2.96 (-39.95%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Shanghai Hile Bio-Technology Co., Ltd.

Why is Shanghai Hile Bio-Technology Co., Ltd. ?

1
  • PRE-TAX PROFIT(Q) At CNY 6.12 MM has Fallen at -89.46%
  • INVENTORY TURNOVER RATIO(HY) Lowest at 0.91 times
  • NET SALES(Q) Lowest at CNY 39.97 MM
2
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -33.85% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shanghai Hile Bio-Technology Co., Ltd. for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
Shanghai Hile Bio-Technology Co., Ltd.
-100.0%
-0.94
34.13%
China Shanghai Composite
15.17%
1.58
14.20%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-1.05%
EBIT Growth (5y)
34.90%
EBIT to Interest (avg)
1.32
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.17
Tax Ratio
13.73%
Dividend Payout Ratio
29.72%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.79%
ROE (avg)
6.32%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.81
EV to EBIT
57.10
EV to EBITDA
39.90
EV to Capital Employed
3.61
EV to Sales
14.72
PEG Ratio
0.05
Dividend Yield
1.13%
ROCE (Latest)
6.32%
ROE (Latest)
13.47%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 258.36 MM

RAW MATERIAL COST(Y)

Fallen by -41.72% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -29.47 %

-23What is not working for the Company
PRE-TAX PROFIT(Q)

At CNY 6.12 MM has Fallen at -89.46%

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.91 times

NET SALES(Q)

Lowest at CNY 39.97 MM

NET PROFIT(Q)

Lowest at CNY 1.16 MM

EPS(Q)

Lowest at CNY 0

Here's what is working for Shanghai Hile Bio-Technology Co., Ltd.

Operating Cash Flow
Highest at CNY 258.36 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Debt-Equity Ratio
Lowest at -29.47 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -41.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Hile Bio-Technology Co., Ltd.

Net Sales
At CNY 39.97 MM has Fallen at -40.74%
over average net sales of the previous four periods of CNY 67.44 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (CNY MM)

Pre-Tax Profit
At CNY 6.12 MM has Fallen at -89.46%
over average net sales of the previous four periods of CNY 58.05 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 1.16 MM has Fallen at -97.49%
over average net sales of the previous four periods of CNY 46.03 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (CNY MM)

Net Sales
Lowest at CNY 39.97 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Net Profit
Lowest at CNY 1.16 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS
Lowest at CNY 0
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Inventory Turnover Ratio
Lowest at 0.91 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio